Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Seema Sethi

Showing results (61-70 of 72) with videos related to

Pageof 8
Sort By:
Plos One|March 24, 2012
Loss of let-7 up-regulates EZH2 in prostate cancer consistent with the acquisition of cancer stem cell signatures that are attenuated by BR-DIMDejuan Kong, Elisabeth Heath, Wei Chen, et al.
The Laryngoscope|December 19, 2013
Serum prognostic biomarkers in head and neck cancer patientsHo-Sheng Lin, Fauzia Siddiq, Harvinder S Talwar, et al.
Oncotarget|September 9, 2017
HPV-associated differential regulation of tumor metabolism in oropharyngeal head and neck cancerYoung-Suk Jung, Abdo J Najy, Wei Huang, et al.
Journal of Translational Medicine|July 16, 2015
Development of patient-derived xenograft models from a spontaneously immortal low-grade meningioma cell line, KCI-MENG1Sharon K Michelhaugh, Anthony R Guastella, Kaushik Varadarajan, et al.
Cancer Letters|April 23, 2013
EZH2 blockade by RNA interference inhibits growth of ovarian cancer by facilitating re-expression of p21(waf1/cip1) and by inhibiting mutant p53Shelly Seward, Assaad Semaan, Aamer M Qazi, et al.
Lung Cancer (Amsterdam, Netherlands)|February 14, 2026
Overall survival for amivantamab plus lazertinib versus osimertinib as first-line treatment in Asian participants with EGFR-mutant advanced NSCLC: A MARIPOSA subset analysisHidetoshi Hayashi, Byoung Chul Cho, Yu Jung Kim, et al.
ACS Medicinal Chemistry Letters|December 1, 2015
Borrelidin Induces the Unfolded Protein Response in Oral Cancer Cells and Chop-Dependent ApoptosisAlpa Sidhu, Justin R Miller, Ashootosh Tripathi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 30, 2026
Long-Term Impact of First-Line Amivantamab Plus Lazertinib Versus Osimertinib on Mechanisms of Acquired Resistance in MARIPOSA: A Brief ReportHidetoshi Hayashi, Byoung Chul Cho, David R Spigel, et al.
Lung Cancer (Amsterdam, Netherlands)|April 29, 2025
Amivantamab plus lazertinib versus osimertinib as first-line treatment in EGFR-mutated advanced non-small cell lung cancer: MARIPOSA Asian subsetByoung Chul Cho, Hidetoshi Hayashi, Jong-Seok Lee, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 5, 2025
Lazertinib Versus Osimertinib in Previously Untreated EGFR-Mutant Advanced NSCLC: A Randomized, Double-Blind, Exploratory Analysis From MARIPOSASe-Hoon Lee, Shun Lu, Hidetoshi Hayashi, et al.
Pageof 8

Showing results (61-70 of 72) with videos related to

Sort By:
Pageof 8
Plos One|March 24, 2012
Loss of let-7 up-regulates EZH2 in prostate cancer consistent with the acquisition of cancer stem cell signatures that are attenuated by BR-DIMDejuan Kong, Elisabeth Heath, Wei Chen, et al.
The Laryngoscope|December 19, 2013
Serum prognostic biomarkers in head and neck cancer patientsHo-Sheng Lin, Fauzia Siddiq, Harvinder S Talwar, et al.
Oncotarget|September 9, 2017
HPV-associated differential regulation of tumor metabolism in oropharyngeal head and neck cancerYoung-Suk Jung, Abdo J Najy, Wei Huang, et al.
Journal of Translational Medicine|July 16, 2015
Development of patient-derived xenograft models from a spontaneously immortal low-grade meningioma cell line, KCI-MENG1Sharon K Michelhaugh, Anthony R Guastella, Kaushik Varadarajan, et al.
Cancer Letters|April 23, 2013
EZH2 blockade by RNA interference inhibits growth of ovarian cancer by facilitating re-expression of p21(waf1/cip1) and by inhibiting mutant p53Shelly Seward, Assaad Semaan, Aamer M Qazi, et al.
Lung Cancer (Amsterdam, Netherlands)|February 14, 2026
Overall survival for amivantamab plus lazertinib versus osimertinib as first-line treatment in Asian participants with EGFR-mutant advanced NSCLC: A MARIPOSA subset analysisHidetoshi Hayashi, Byoung Chul Cho, Yu Jung Kim, et al.
ACS Medicinal Chemistry Letters|December 1, 2015
Borrelidin Induces the Unfolded Protein Response in Oral Cancer Cells and Chop-Dependent ApoptosisAlpa Sidhu, Justin R Miller, Ashootosh Tripathi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 30, 2026
Long-Term Impact of First-Line Amivantamab Plus Lazertinib Versus Osimertinib on Mechanisms of Acquired Resistance in MARIPOSA: A Brief ReportHidetoshi Hayashi, Byoung Chul Cho, David R Spigel, et al.
Lung Cancer (Amsterdam, Netherlands)|April 29, 2025
Amivantamab plus lazertinib versus osimertinib as first-line treatment in EGFR-mutated advanced non-small cell lung cancer: MARIPOSA Asian subsetByoung Chul Cho, Hidetoshi Hayashi, Jong-Seok Lee, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 5, 2025
Lazertinib Versus Osimertinib in Previously Untreated EGFR-Mutant Advanced NSCLC: A Randomized, Double-Blind, Exploratory Analysis From MARIPOSASe-Hoon Lee, Shun Lu, Hidetoshi Hayashi, et al.
Pageof 8